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Background/aim: The aim of this study was to investigate the effect of vitamin D on the disease prognosis and biochemical
parameters in patients with mild obstructive sleep apnea syndrome (OSAS).
Materials and methods: Nineteen adult male individuals (18–65 years) who were diagnosed with mild OSAS after polysomnography
and had low vitamin D levels were included in the study. Each week, patients took 50.000 IU Vitamin D3 supplementation for 8 weeks.
Polysomnography, biochemical parameters FBG (fasting blood glucose), lipid profile (TG, TC, LDL-C, HDL-C, VLDL-C), calcium,
phosphorus, parathormone, calcitonin, serum 25(OH)D, insulin, CRP, TNF-α, IL-6, and IL-10 of patients were evaluated at the beginning
of study and at the end of the study. All assessments, including polysomnography, were repeated after 8 weeks.
Results: Serum vitamin D levels were initially 19.5 ± 5.01 ng/mL and increased to 41.8 ± 10.51 ng/mL (p < 0.001) at the end of the
study. FBG, TC and HOMA-IR of the patients were significantly decreased (p < 0.05). CRP, TNF-α, IL-6, and IL-10 levels were also
correlated with serum vitamin D levels (p < 0.05). There was a significant decrease in number of obstructive apneas, apneas and
hypopneas, apnea index, hypopnea index, and apnea hypopnea index of the patients (p < 0.05).
Conclusion: As a result, it is thought that vitamin D supplementation may have a positive effect on the disease prognosis of mild OSAS.
Key words: Vitamin D supplementation, obstructive sleep apnea, biochemical parameters, inflammation

1. Introduction
Among the sleep disorders, obstructive sleep apnea
syndrome (OSAS) has the highest prevalence (1%–5%)
[1,2]. OSAS is defined as a disease with daytime sleepiness,
loud snoring and witnessed apnea in the presence of at
least five airway obstructions per hour in sleep [2].
Obstructive sleep apnea syndrome is not only a disease
affecting daily life, but associated with many diseases such
as coronary artery disease, diabetes mellitus (DM) and
stroke as well [3,4]. These diseases accompanying OSAS
and OSAS itself have been found to be associated with the
inflammatory process, and proinflammatory mediators
(IL-1 beta, IL-6, IL-8, CRP, and TNF-𝛼) have been seen to
increase in these diseases [5,6]. Besides, intermittent
hypoxia induces inflammation and causes impairment in
lipid metabolism or stimulation of lipolysis [7,8]. The
hyperlipidemia resulting from excessive lipolysis [7]
triggers insulin resistance and inflammation [8].
Polysomnography (PSG) is the gold standard
technique in the diagnosis of OSAS [9], and continuous
positive airway pressure (CPAP) is the gold standard
treatment in patients with moderate and severe OSAS
with apnea-hypopnea index (AHI)> 15. However, CPAP
treatment is recommended in mild obstructive sleep
apnea (OSA) (AHI: 5–15) if symptoms are pronounced

and/or in the presence of cardiovascular and
cerebrovascular risk factors [10]. Since the severity of
mild OSAS worsens over time, it is also thought that active
and effective treatment may be required for mild OSAS.
Although severe OSA is associated with an increased risk
of cardiovascular disease (CVD), mild OSA is associated
with a higher prevalence of CVD and significant
cardiovascular (CV) comorbidity [11]. In addition, if OSA
is not treated, the risk development of CVD may increase
[12]. Despite these risks, it has been emphasized that the
acceptance rate of CPAP is low in mild OSAS [11]. In a
study, while the rate of acceptance to use CPAP is 61.88%
in severe OSAS and 37.37% in moderate OSAS, this rate is
only 10% in mild OSAS (p < 0.001) [11]. It has been
reported that getting the device for a certain fee or the
high price of the device affects its use, and the rate of use
increases in the countries where the CPAP device is
provided free of charge [11].
As stated in the consensus report of OSAS in Turkey,
the gold standard treatment method in OSAS is positive
airway pressure (PAP) treatment. However, contrary to
current scientific practices, in order to report devices such
as air pressure/bilevel positive airway pressure
(CPAP/BPAP) in the practices of Social Security
Institution (SSI), “the apnea index (AI) must be at least 15
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or apnea-hypopnea index (AHI) must be at least 30, or the
respiratory disturbance index (RDI) must be at least 30”.
If the RDI is between 5 and 30, costs of the devices are
covered by the institution if some risk factors
accompanying OSAS (daytime sleepiness, hypertension,
cognitive impairment) are reported [10].
Recently, vitamin D deficiency has been reported to
play a role in the development of sleep disorders [13]. It
was observed that serum 25-hydroxyvitamin D
(25(OH)D) level was lower in OSAS than in the control
group [14]. Some studies have shown that serum 25(OH)D
levels decrease as OSAS intensity increases [15–17].
Vitamin D deficiency has been reported to pose a risk for
OSAS by causing increased adenotonsillar hypertrophy,
airway muscle myopathy, and/or chronic rhinitis [13].
Chronic low serum vitamin D level also increases the risk
of restriction in nasal airflow [13]. In addition, low serum
vitamin D levels cause an increased risk of diseases such
as autoimmune diseases, chronic rhinitis, CVD, diabetes,
and tonsillar hypertrophy. This is associated with an
increase in inflammatory cytokines (TNF-𝛼, IL-1, and
prostaglandin D2 (PD2)), which are also effective in
regulating sleep, with the change of immunomodulation
and increased susceptibility to infections [13]. Besides,
the level of IL-6 increase [18] and serum 25(OH)D level
decrease in OSAS [19]. In human studies, they have
attributed high serum vitamin D levels to a decrease in
inflammatory cytokines such as CRP, IL-6, and TNF-α in
healthy individuals [20,21]. The same relationship has
been observed in proinflammatory conditions such as
diabetes, atherosclerosis, and inflammatory polyarthritis
[19]. While high serum vitamin D is known to have
positive effects in the inflammatory process, the effect of
continuous positive airway pressure (CPAP) treatment
applied in the treatment of OSAS on inflammation is
contradictory [22–24].
The low rate of CPAP acceptance/use in mild OSAS
suggests that different treatment practices should be tried
in mild OSAS. Studies on vitamin D supplementation in
OSAS are limited in the literature. The aim of this study is
to evaluate the effects of vitamin D supplementation on
disease prognosis and biochemical parameters in
individuals who do not have a routine treatment, do not
accept CPAP use, and have a diagnosis of mild OSAS with
vitamin D deficiency.
2. Materials and methods
Nineteen male volunteer adults with vitamin D deficiency
(<30 mg/dL) were included in this study. They aged
between 19 and 64 and applied to Gazi University Faculty
of Medicine, Sleep Disorders Center between March 2016
and May 2018 with the complaint of sleep disorder. They
were diagnosed with mild OSAS after fullnight
polysomnography (AHI: 5–15). Since this disease is seen
more frequently in men and the proportion of men
applying to the study center is higher, only male
individuals were included in the study. A group of patients
who did not receive/accept any treatment including CPAP

was studied. The power was calculated with Minitab 16.0
program. According to the program, the full power was
calculated as 85.59% for 19 individuals.
Those who took vitamin-mineral or fish oil
supplements in the last 6 months, who had liver and
kidney dysfunction, those who had normal vitamin D
levels, those who take a medication affecting vitamin D
level (such as steroids and anticonvulsant), who are
diagnosed with cancer, who follow a diet, and those who
do not want to participate in the study were excluded.
Vitamin D supplementation is also contraindicated in
patients with vitamin D hypervitaminosis, hypercalcemia,
hypercalciuria, calcium-containing kidney stones, and
calcium hypersensitivity. Therefore, these patients were
not included in the study.
2.1. Research plan
Forty patients who met the determined criteria were
included in the study. Vitamin D supplementation (D3 oral
solution) was applied to all individuals for 8 weeks. PSG
findings, biochemical parameters (fasting blood glucose
(FBG), lipid profile, calcium, phosphorus, parathormone,
calcitonin, (25(OH)D), insulin, C-reactive protein (CRP),
tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6),
and interleukin-10 (IL-10) were evaluated at the
beginning and after 8 weeks. However, two patients
refused to take vitamin D supplementation at the
beginning of the study; 14 patients initially agreed to be
included in the study but did not take a vitamin D
supplementation regularly; 4 patients did not agree to
come for analysis to be performed at the end of the study
although they regularly took vitamin D supplementation
for 8 weeks. One of the participants did not accept PSG for
the second time, so only blood findings were analyzed. For
these reasons, the study was completed with 19 patients
(Figure).
2.2. Evaluation of polysomnography
All individuals included in the study were diagnosed with
mild OSAS with an AHI value between 5–15 from
polysomnography (PSG) [25] performed at Gazi
University Faculty of Medicine, Sleep Disorders Center for
one night. At the end of the study, PSG was repeated. The
Natus neurology Grass Technologies (Twin PSG Clinical
Software) was used for PSG. The scoring PSG was
performed manually by the same person.
2.3. Vitamin D supplementation
It was recommended to take 50.000 IU vitamin D
supplement once a week for individuals with an initial
serum 25(OH)D level of <30 ng/mL for 8 weeks according
to the recommendation of the Endocrine Society [26].
Individuals included in the study were reminded by phone
every week that they should receive supplementations.
2.4. Biochemical parameters
Blood samples were taken at the beginning and end of the
study after 8 hours of fasting and in pyrogen-free tubes.
Calcium, phosphorus, parathormone, calcitonin, 25(OH)D,
insulin, CRP, cytokines (TNF-α, IL-6, and IL-10) analyses
of the biochemical parameters of these samples fasting
2525
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Figure. Study flow.

blood glucose (FBG), lipid profile (triglyceride (TG), total
cholesterol (TC), low density lipoprotein cholesterol
(LDL-C), high density lipoprotein cholesterol (HDL-C),
very low density lipoprotein cholesterol (VLDL-C) were
done at Gazi University Central Biochemistry Laboratory.
Serum FBG, lipid profile, calcium, and phosphorus levels
were studied with photometric method by using autoanalyzer (Beckman Coulter AU5800) and using ready to
use kits (Beckman Coulter). Serum parathormone, insulin,
and serum 25(OH)D levels were studied with
chemiluminescent method by using auto-analyzer
(Beckman Coulter DXI 800) and ready to use kits
(Beckman Coulter). Serum calcitonin levels were studied
with chemiluminescent method by using auto-analyzer
(Siemens Immulite 2000 XPI) and ready to use kits
(Siemens). Serum CRP levels were studied with
nephelometric method. In the analysis of cytokines, ELISA
method was employed by using ready to use kits
(Diasource).
Individuals’ blood glucose, insulin level, and
homeostatic model assessment insulin resistance (HOMAIR) were calculated as HOMA-IR = fasting glucose (mg/dL)
X fasting insulin (uIU/mL)/405 and individuals with
HOMA value ≥2.7 are considered to have insulin
resistance [27].
2.5. Statistical evaluation of data
The obtained data were evaluated in SPSS v. 22.0
statistical package program. The information about the
categorical variables of the individuals is given in terms of
frequency and percentage, and differences were
examined with chi-square (2) analysis. For the
̅ ) and median,
assessment of quantitative data, mean (𝑥
standard deviation (SD), and lower and upper values were
tabulated. The normality of the distributions was
examined with the Kolmogorov–Smirnov test. HDL-C,
calcitonin, TG, parathormone show normal distribution,
while other biochemical parameters do not show normal
distribution. For variables with normal distribution,
paired-sample t test in paired differences, and the
differences of those without normal distribution
assumption were examined with Wilcoxon sign test. Also,
the t-test was used for number of respiratory events
during the entire sleep, nonrapid eye movement (NREM)
sleep phase and supine position (total apnea, hypopnea,
apnea + hypopnea). The Wilcoxon sign test was used to
evaluate respiratory events in rapid eye movement (REM)
2526

sleep phase and nonsupine position. The correlation
between biochemical parameters and the mean serum
25(OH)D levels of individuals was used Spearman
correlation. All examinations were made statistically and
interpreted at a 95% confidence level. In order to
highlight the significance, values with p < 0.05 are shown
in the table with (*).
3. Results
This study included 19 volunteer male individuals
diagnosed with mild OSAS. The mean age of the patients is
44.1 ± 10.39 years (23–63 years). 63.2% of individuals
have undergraduate and graduate education. While the
rate of self-employed is 52.6%, the rate of civil servants is
21.1%. The marital status of 94.7% of the participants in
the study is married. In 47.4% of individuals, there are
additional diseases other than OSAS. Cardiovascular
diseases are present in 44.4% of those diagnosed with
additional diseases, while nervous system diseases are
present in 33.0%. In initial of study, the mean BMI of
individuals was 28.3 ± 3.49 kg/m2 and 28.4 ± 3.41 kg/m2
at the end of the study (p = 0.133). It was observed that
the rate of obese individuals (BMI ≥ 30 kg/m2) was the
same (31.6%) at the beginning and end of the study.
During the period from the beginning to the end of the
study, no suggestions regarding nutrition and physical
activity were made to the patients and no changes were
made. In addition, there was no significant difference
between individuals' body weight at the beginning and
end of the study (p > 0.05) (not shown in the table).
3.1. Vitamin D levels of individuals
Vitamin D levels of individuals (n:19) are shown in Table
1. Serum vitamin D level was 19.5 ± 5.01 ng/mL before
vitamin D supplementation while it increased to 41.8 ±
10.51 ng/mL after vitamin D supplementation (p < 0.001).
According to initial serum vitamin D level of the
individuals, 52.6% of the individuals were deficient and
47.4% of them were insufficient. At the end of the study,
there was no individual with a deficiency of vitamin D
while 89.5% of them had sufficient vitamin D levels. When
the exposure of individuals to daylight was questioned, it
was 51.1 ± 48.66 min/day (10.0–180.0 min/day) at the
beginning while it was 58.2 ± 63.03 min/day (15.0–240.0
min/day) (p > 0.05) at the end of the study (not shown in
the table).
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3.2. Biochemical parameters of individuals
The evaluation of individuals' biochemical parameters at
the beginning and end of the study is shown in Table 2.
While the mean FBG level was 95.7 ± 7.97 mg/dL at the
beginning of the study, it decreased to 90.0 ± 8.26 mg/dL
after vitamin D supplementation, and the mean HOMA-IR
values decreased from 2.3 ± 1.09 to 1.8 ± 0.83. These
decreases are statistically significant (p = 0.003 and p =
0.040, respectively). It was found that initial TC level
decreased from 206.8 ± 43.55 mg/dL to 188.3 ± 53.17
mg/dL, and this decrease was statistically significant (p =
0.044). Although the initial mean serum HDL-C, LDL-C,
VLDL-C, calcium, phosphorus, parathormone, calcitonin,
insulin, CRP, TNF-α, IL-6, and IL-10 levels decreased at the
Table 1. Vitamin D levels of individuals (%).
Initial

Final

Serum 25(OH)D level
(ng/mL)
<20 (insufficiency)

n

%

n

%

10

52.6

-

-

20–30 (deficiency)

9

47.4

2

10.5

30–100 (normal)

-

-

17

89.5

19.5 ± 5.01
41.8 ± 10.51
ng/mL
ng/mL*
*(p < 0.001). Since the number of observations is insufficient,
statistical difference could not be evaluated in other
parameters.

end of the study, this difference was not statistically
significant (p > 0.05). Although the mean TG levels of
individuals increased at the end of the study, this increase
was not significant (p = 0.709).
Correlation of biochemical parameters according to
the mean serum 25(OH)D levels of individuals is given in
Table 3. Initially, there was no significant correlation
between vitamin D levels and biochemical findings (p >
0.05). After the supplementation, a significant negative
correlation was observed between vitamin D level and
levels of CRP (r: –0.477 p = 0.034), TNF-α (r: –0.450 p =
0.047), and IL-6 (r: –0.560 p = 0.010); while a significant
positive correlation was found with IL-10 (r: 0.549 p =
0.012) level.
3.3. Evaluation of polysomnography results of
individuals
According to the polysomnography (PSG) results of the
individuals, the number of respiratory events during the
entire sleep is shown in Table 4. After using vitamin D
supplements, the mean AHI decreased from 8.9 ± 2.05 to
5.5 ± 2.43 (p < 0.001). At the same time, the number of
apnea + hypopnea, apnea index, and hypopnea index
decreased significantly (p = < 0.001, p = 0.015 and p =
0.004, respectively). There was a significant decrease in
the number of obstructive apnea (p = 0.012), as well as a
significant decrease in the number of all apneas (p =
0.012) and the number of hypopneas (p = 0.001) (Table

Table 2. The evaluation of individuals' biochemical parameters (𝑥̅ ±SD).
Initial

Median

Min

Max

Final

Median

Min

Max

Z/t

p

FBG (mg/dL)

95.7 ± 7.97

94.5

80.0

112.0

90.0 ± 8.26

90.0

68.0

105.0

–3.474

0.003*

TC (mg/dL)

206.8 ±
203.5
43.55
41.8 ± 10.10 41.0

127.0

286.7

22.4

265.3

–2.016

0.044*

25.8

65.0

188.3 ±
189.3
53.17
41.7 ± 10.20 39.9

25.2

62.6

–0.205

0.837

130.4 ±
131.7
34.57
34.4 ± 20.19 27.5

73.2

187.0

78.0

170.0

–0.900

0.380

13.2

102.1

126.7 ±
120.9
28.48
31.0 ± 14.55 27.8

11.7

72.0

–1.344

0.179

137.5

66.4

508.0

58.5

656.7

–0.373

0.709

9.6

9.2

10.2

175.8 ±
130.28
9.5 ± 0.30

139.4

Calcium (mg/dL)

172.4 ±
100.69
9.6 ± 0.27

9.4

8.8

10.0

–1.809

0.086

Phosphorus (mg/dL)

3.3 ± 0.46

3.3

2.4

4.47

3.2 ± 0.45

3.2

2.2

4.1

–0.752

0.461

Parathormone
(pg/mL)
Calcitonin (pg/mL)

49.2 ± 23.96 43.7

23.4

136.2

44.3 ± 18.99 35.7

21.1

89.0

–0.747

0.455

4.9 ± 6.12

2.6

2

28.1

4.4 ± 5.27

2.2

2.0

24.0

–1.363

0.173

Insulin (ng/mL)

10.0 ± 4.75

9.9

3.2

22.5

8.0 ± 3.45

8.5

2.87

12.8

–1.814

0.085

HOMA-IR

2.3 ± 1.09

2.2

0.7

4.9

1.8 ± 0.83

1.7

0.6

3.28

–2.202

0.040*

25(OH)D (ng/mL)

19.5 ± 5.01

18.5

11.0

27.7

41.7 ± 10.51 42.0

22.98

67.0

9.439

<0.001*

CRP (mg/L)

3.0 ± 1.01

3.0

1.4

5.85

2.8 ± 0.71

3.0

1.8

4.8

–1.587

0.129

TNF-α (pg/mL)

13.3 ± 26.36 7.1

3.8

124.8

12.6 ± 13.79 8.1

4.4

67.7

–1.791

0.073

IL-6 (pg/mL)

28.3 ± 7.81

26.1

191

48.7

27.7 ± 8.87

25.2

17.8

48.2

–0.915

0.360

IL-10 (pg/mL)

5.5 ± 6.35

3.8

1.8

31.8

5.5 ± 4.87

4.8

1.8

24.8

–0.819

0.413

HDL-C (mg/dL)
LDL-C (mg/dL)
VLDL-C (mg/dL)
TG (mg/dL)

*p < 0.05. FBG: Fasting blood glucose, HDL-C: High density lipoprotein cholesterol, LDL-C: Low density lipoprotein cholesterol,
VLDL-C: Very low density lipoprotein cholesterol, TC: Total cholesterol, TG: Triglyceride, HOMA-IR: Homeostatic model assessment
insulin resistance, 25(OH)D: 25-hydroxyvitamin D, CRP: C-reactive protein, TNF-α: Tumor necrosis factor alpha, IL-6: Interleukin-6,
IL-10: Interleukin-10.
2527
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Table 3. Correlation of biochemical parameters according to
the mean serum 25(OH)D levels of individuals.
Initial
Final
r

p

r

p

FBG (mg/dL)

–0.399

0.081

–0.396

0.084

TC (mg/dL)

–0.065

0.786

–0.542

0.014*

HDL-C (mg/dL)

0.221

0.349

–0.282

0.228

LDL-C (mg/dL)

–0.255

0.278

–0.506

0.023*

VLDL-C (mg/dL)

–0.072

0.764

–0.108

0.649

TG (mg/dL)

–0.072

0.764

–0.047

0.845

Calcium (mg/dL)

–0.005

0.982

–0.264

0.262

Phosphorus (mg/dL)

0.070

0.768

–0.222

0.347

Parathormone (pg/mL) –0.176

0.458

–0.423

0.063

Calcitonin (pg/mL)

0.305

0.190

–0.178

0.452

Insulin (uIU/mL)

–0.186

0.431

–0.079

0.741

HOMA-IR

–0.245

0.297

–0.109

0.647

CRP (mg/L)

–0.223

0.344

–0.477

0.034*

TNF-α (pg/mL)

0.047

0.843

–0.450

0.047*

IL-6 (pg/mL)

–0.171

0.470

–0.560

0.010*

IL-10 (pg/mL)
–0.269 0.251 0.549
0.012*
* p < 0.05. FBG: Fasting blood glucose, HDL-C: High density
lipoprotein cholesterol, LDL-C: Low density lipoprotein
cholesterol, VLDL-C: Very low density lipoprotein cholesterol,
TC: Total cholesterol, TG: Triglyceride, HOMA-IR: Homeostatic
model assessment insulin resistance, 25(OH)D: 25hydroxyvitamin D, CRP: C-reactive protein, TNF-α: Tumor
necrosis factor alpha, IL-6: Interleukin-6, IL-10: Interleukin-10.

4). According to the PSG results of individuals, respiratory
events were evaluated in the NREM sleep phase (Table 4).
It was seen that there was a significant decrease in AHI
value after supplementation (p = 0.002). While the
decrease in the number of obstructive apnea was not
significant, the decrease in the number of all apneas was
statistically significant (p = 0.035). At the same time, the
number of hypopnea, apnea + hypopnea, and hypopnea
index also decreased significantly after the take of vitamin
D (p <0.05). When respiratory events were evaluated in
REM sleep phase according to the PSG results of
individuals, in addition to the significant decrease in AHI
value (p = 0.005) in the REM stage after using vitamin D,
the number of obstructive apnea, the number of all
apneas, the number of hypopnea, the number of apnea +
hypopnea, and the hypopnea index also decreased
significantly (p < 0.05) (Table 4).
According to PSG results of individuals, respiratory
events were evaluated according to the nonsupine/supine
sleep position (Table 5). The initial AHI value in the
nonsupine position was an average of 4.3 ± 3.84, and then
it decreased to 2.7 ± 3.99. However, while the decrease in
AHI value was not significant, it was seen that there was a
significant decrease only in the number of apnea +
hypopnea (p = 0.017). According to the supine sleep
position, the AHI value at the beginning of the study was
16.3 ± 12.34, then it decreased to 12.2 ± 9.57 at the end of
2528

the study (p = 0.009). In addition, the number of hypopnea
and apnea + hypopnea decreased significantly (p < 0.05).
Oxygen desaturation index (ODI) decreased
significantly after using vitamin D in NREM (p = 0.027)
and REM (p = 0.016). When the desaturation status of
individuals was evaluated according to the PSG results
during the entire sleep period, ODI decreased significantly
at the end of the study (p = 0.014). There was no
significant change in the mean oxygen saturation (SpO2).
Although an increase in sleep time was observed in
individuals with SpO2 > 90% after vitamin D
supplementation, this increase was not significant (p =
0.053) (Not shown in the table).
4. Discussion
Obstructive sleep apnea syndrome is a disease affecting
daily life and associated with many diseases such as
coronary artery disease, diabetes mellitus, and stroke
[3,4]. When OSAS is not treated, it is difficult to control
blood pressure and the risk of developing CVD such as
arrhythmias, coronary artery diseases, congestive heart
diseases, stroke may increase [12]. The importance of
early and accurate diagnosis of OSAS is important in terms
of both improving individuals’ health and preventing the
burden it can put on healthcare [28]. PAP treatment is safe
and effective, and its side effects are minor and reversible
[29]. However, the rate of accepting to use CPAP in OSAS
has been found to be low [11].
It has been reported that serum 25(OH)D levels are
lower in individuals with OSAS than healthy individuals,
and the level of vitamin D decreases as OSAS severity
increases [14–17]. On the contrary, Li et al. [30], showed
that the serum 25 (OH) D level was not decreased in mild
OSA patients compared with the controls. However, the
serum 25 (OH) D level in moderate and severe OSA
patients was lower than that in the controls. Liguori et al.
[31] reported that serum 25(OH)D deficiency for OSAS is
a risk factor for men. In the study, the mean serum vitamin
D of male individuals was 19.5 ± 5.01 ng/mL while it
increased to 41.8 ± 10.51 ng/mL after supplementation (p
< 0.001). In another study, as a result of the vitamin D
supplement given to 200 individuals for 6 months, it was
observed that only 60 individuals had a statistically
significant level of vitamin D increase (normal level) [32].
In this study, while the vitamin D level of individuals was
in the “deficient” class before vitamin D supplementation,
89.5% (n: 17) of the vitamin D level reached a sufficient
level after supplementation. For those who do not reach a
sufficient level despite vitamin D support, it is thought
that vitamin D supplementation will depend on duration
and individual differences such as VDR polymorphism
differences, genetics, age, and BMI.
An increase in TC, LDL-C, VLDL-C, TG levels, and a
decrease in HDL-C level pose a risk for CVD [33]. In a
study, LDL-C decreased significantly and HDL-C increased
significantly in individuals diagnosed with OSAS after
vitamin D supplementation (n:10). However, in that study,
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Table 4. The number of respiratory events during the entire sleep according to the polysomnography (PSG) results of the
individuals (𝑥̅ ±SD).
Initial
Final
𝑥̅ ±SD

Median Min Max 𝑥̅ ±SD

Median Min Max Z/t

p

Number of respiratory events during the entire
sleep

Apnea index

18.7 ±
13.30
22.4 ±
14.93
34.7 ±
17.69
59.0 ±
17.57
3.8 ± 1.94

Hypopnea index
AHI

Obstructive apnea
Total apnea

17.0

0.0

45.0 10.3 ± 8.56 9.0

0.0

31.0 –2.787 0.012*

21.0

0.0

58.0 13.3 ± 9.12 12.0

0.0

33.0 –2.803 0.012*

30.0

7.0

18.0

5.0

58.0 –3.960 0.001*

33.0

11.0 70.0 –5.195 <0.001

2.4

0.1

5.4

–2.727 0.015*
–3.419 0.004*

3.4

22.3 ±
15.33
35.6 ±
34.0 98.0
16.51
0.6 7.8 2.3 ± 1.44

4.8 ± 2.30

4.6

1.1

9.1

3.0 ± 1.96

2.8

1.1

8.3

8.9 ± 2.05

8.8

5.9

12.3 5.5 ± 2.43

5.1

1.4

10.8 –5.768 <0.001

Obstructive apnea

10.9 ±12.42 7.0

0.0

39.0 6.1 ± 5.17

5.0

0.0

19.0 –1.951 0.067

Total apnea

14.2 ±13.94 10.0

0.0

40.0 8.4 ± 6.57

8.0

0.0

21.0 –2.285 0.035*

Hypopnea

18.3 ± 9.18 18.0

2.0

39.0 13.1 ± 8.47 11.0

2.0

31.0 –2.715 0.014*

Apnea + hypopnea

32.4 ±16.25 33.0

7.0

59.0 21.5 ± 9.92 20.0

6.0

36.0 –3.640 0.002*

Apnea index

3.1 ± 2.74

2.2

0.2

8.8

2.0 ± 1.57

1.7

0.2

6.3

–2.047 0.570

Hypopnea index

3.7 ± 1.87

3.6

0.3

8.5

2.9 ± 2.26

2.4

0.5

9.1

–2.448 0.026*

AHI

7.3 ± 3.26

7.7

1.2

13.3 4.5 ± 1.86

4.9

1.0

7.6

–3.684 0.002*

Obstructive apnea

7.6 ± 7.89

3.0

0.0

20.0 4.0 ± 6.32

1.0

0.0

23.0 –2.260 0.024*

Total apnea

8.6 ± 8.57
12.5 ±
10.42

8.0

0.0

24.0 4.6 ± 6.48

2.0

0.0

23.0 –2.204 0.028*

10.5

0.0

30.0 6.1 ± 8.31

3.0

0.0

35.0 –2.562 0.010*

Apnea + hypopnea

23.4 ± 17.2 24.0

0.0

60.0

5.0

0.0

38.0 –3.289 0.001*

Apnea index

5.8 ± 5.23

5.1

0.0

10.4 ±
12.20
14.0 3.9 ± 5.31

1.6

0.0

17.9 –1.293 0.196

Hypopnea index

8.7 ± 7.23

9.4

0.0

21.0 4.3 ± 5.25

2.4

0.0

20.2 –2.045 0.041*

AHI
14.1 ± 9.89 14.7
0.0 35.1 7.9 ± 9.06 4.1
*p < 0.05. AHI: apnea hypopnea index, NREM: nonrapid eye movement, REM: rapid eye movement.

0.0

30.5 –2.809 0.005*

Hypopnea
Apnea + hypopnea

60.0

63.0

Respiratory events in NREM sleep phase

Respiratory events in REM sleep phase

Hypopnea

it was stated that 90.0% of individuals received CPAP
treatment as well as vitamin D supplementation [34].
There is another study showing that CPAP treatment
reduces LDL-C and TC and increases HDL-C [35].
Therefore, whether this effect is a result of vitamin D or
CPAP has not been revealed clearly. In this study, a group
of patients with mild OSAS who did not receive/accept any
treatment, including CPAP was studied. At the end of the
study, TC level decreased significantly and after vitamin D
supplementation, a significant negative relationship
between serum vitamin D level and some parameters (TC
level (r: –0.475 p = 0.033) and LDL-C level (r: –0.446 p =
0.049)) was revealed. Barbalho et al. [36] reported that
vitamin D supplementation caused a significant decrease
in TC, and a negative significant correlation between TC
and LDL-C and serum vitamin D levels would have a
positive effect for CVD. The positive contribution of
vitamin D to the lipid profile may be due to the anti-

inflammatory effect of vitamin D and reducing oxidative
stress [33]. This study suggests that the positive effect of
vitamin D supplementation on the lipid profile may have a
positive effect against the risk of developing CVD in OSAS.
In OSAS, proinflammatory mediators have been shown
to increase IL-1 beta, IL-6, IL-8, CRP, and TNF-𝛼 [5,6].
Serum vitamin D is thought to have a positive effect on
cardiovascular health by inhibiting inflammatory cytokine
release [32]. Although it is thought that low vitamin D
level may increase systemic inflammation [13], it is
emphasized that the anti-inflammatory response that
plays a role in the relationship between metabolic
dysfunction and OSAS is not clear [37]. In individuals
diagnosed with mild and moderate OSAS, no significant
change in plasma IL-6, IL-10, CRP, or TNF-α has been
reported after 6 months of CPAP treatment [23]. At the
end of this study, although serum CRP, TNF-α, and IL-6
levels decreased in this study, this decrease was not
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Table 5. The number of respiratory events according to the nonsupine/supine sleep position (𝑥̅ ±SD).
Initial

Final

𝑥̅ ± SD

Median

Min

Max

𝑥̅ ± SD

Median

Min

Max

Z/t

p

Obstructive apnea

4.3 ± 6.97

1.0

0.0

27.0

1.4 ± 2.00

1.0

0.0

7.0

–1.789

0.074

Total apnea

5.2 ± 7.01

2.0

0.0

27.0

2.2 ± 2.49

1.0

0.0

7.0

–1.566

0.117

Hypopnea

6.9 ± 6.16

5.0

0.0

22.0

5.1 ± 9.67

2.0

0.0

43.0

–0.865

0.398

Apnea + hypopnea

12.0 ± 9.15

12.0

0.0

39.0

7.3 ± 11.1

4.0

0.0

50.0

–2.395

0.017*

Apnea index

2.1 ± 3.37

1.2

0.0

13.7

0.8 ± 1.07

0.4

0.0

4.1

–1.320

0.187

Hypopnea index

2.1 ± 2.23

1.5

0.0

8.3

1.8 ± 3.19

0.7

0.0

10.6

–0.983

0.326

AHI

4.3 ± 3.84

2.8

0.0

14.2

2.7 ± 3.99

1.4

0.0

14.7

–1.871

0.061

Obstructive apnea

14.1 ± 11.69

13.0

0.0

39.0

8.6 ± 8.92

8.0

0.0

31.0

–1.636

0.102

Total apnea

17.4 ± 12.91

14.0

0.0

46.0

10.7 ± 9.30

9.0

0.0

33.0

–1.824

0.085

Hypopnea

26.5± 13.21

24.0

6.0

51.0

14.3 ± 9.54

11.0

5.0

37.0

–3.161

0.002*

Apnea + hypopnea

44.0 ± 15.73

41.0

19.0

74.0

25.0 ± 15.14

20.0

8.4

68.0

–3.860

0.001*

Apnea index

7.4 ± 8.89

4.2

1.1

39.3

4.7 ± 3.75

3.5

0.2

14.5

–1.492

0.136

Hypopnea index

8.8 ± 5.21

8.2

1.3

20.2

7.4 ± 7.95

4.5

1.1

29.0

–2.509

0.012*

13.5

4.5

59.5

12.2 ± 9.57

9.3

2.6

34.8

–2.604

0.009*

Nonsupine position

Supine position

AHI
16.3 ± 12.34
*p < 0.05. AHI: apnea hypopnea index.

statistically significant (p > 0.05). However, there was a
statistically significant negative correlation between
vitamin D and proinflammatory cytokines after
supplementation (r: –0.477 p = 0,034; r: –0.450 p = 0.047;
r: –0.560 p = 0.010, respectively), and a positive
correlation (r: 0.549 p = 0.012) was found with IL-10,
which is an anti-inflammatory cytokine. This effect of
vitamin D [13], which is directly related to inflammation,
is thought to contribute positively to the disease
prognosis.
It is predicted that insulin resistance and
inflammation, which is common in OSAS, can be improved
by vitamin D supplementation [38]. Low vitamin D levels
are known to be associated with hyperglycemia,
hyperinsulinemia, decreased beta cell function, and
insulin resistance [39]. In one study, the intervention
group was given 50.000 IU of vitamin D once a week for 8
weeks, and it was observed that FBS decreased
significantly in both groups compared to the baseline.
While the fasting insulin level and HOMA-IR decreased
significantly in the group receiving the supplement, there
was no difference in BMI value compared to the baseline
[40]. Similarly, in this study, it was observed that FBS and
HOMA-IR values decreased significantly, but the decrease
in insulin level was not significant. In another study,
individuals with a diagnosis of OSAS (n: 10) showed a
significant decrease in FBS after vitamin D
supplementation. However, in that study, it was seen that
90.0% of individuals received CPAP treatment as well as
vitamin D supplementation [34]. It is thought that there is
a need for a further study to examine the effect of vitamin
D supplement to be applied with CPAP.
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Because CPAP, which is the gold standard treatment in
patients with OSAS, has relatively poor compatibility, 31%
of patients with OSAS who have been prescribed CPAP
never starts treatment, and 15% of individuals stops using
the device after 10 months of use ever starts [41], an
active and effective alternative treatment may be required
for mild OSAS [11]. In this study, the effects of vitamin D
supplementation on disease findings in mild OSAS
patients with vitamin D insufficiency were investigated,
and after using vitamin D supplements, the mean AHI of
patients decreased from 8.9 ± 2.05 to 5.5 ± 2.43 (p <
0.001). In addition to the significant decrease in the
number of obstructive apnea (p = 0.012), a significant
decrease was seen in the number of all apneas (p = 0.012)
and the number of hypopneas (p = 0.001). Apnea +
hypopnea number, apnea index, and hypopnea index also
decreased significantly (p = < 0.001, p = 0.015 and p =
0.004, respectively). There was a significant decrease in
the number of obstructive apnea (p = 0.012), as well as a
significant decrease in the number of all apneas (p =
0.012) and the number of hypopneas (p = 0.001). In
addition, there was a significant positive correlation
between serum vitamin D level and sleep efficiency and
continuity (r: 0.666 p = 0.002 and r: 0.627 p = 0.007,
respectively). It is thought that the take of vitamin D in
treatment, due to its positive effects, in mild OSAS patients
with insufficient of vitamin D will have a positive effect on
the prognosis of the disease.
In adults, it is characteristic that upper respiratory
tract obstructions are seen in NREM sleep in OSAS [42]. In
this study, it was seen that there was a significant decrease
in the NREM sleep period AHI value and the number of
total apnea (p < 0.05). At the same time, the number of
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hypopnea, apnea + hypopnea, and hypopnea index
decreased significantly after the use of vitamin D (p <
0.05). Also, it is known that REM related sleep disorder is
more common in mild and moderate OSAS. The low tonus
experienced in the muscles during sleep causes atony
especially by peaking in the REM stage, and respiratory
disorders have been reported to occur more easily. It is
also emphasized that sleep-related respiratory
disturbance associated with REM is the initial stage of
OSAS [43]. In the REM stage after supplementation, the
AHI value, the number of obstructive apnea, the number
of all apneas, the number of hypopnea, the number of
apnea + hypopnea, and the hypopnea index also
decreased significantly (p < 0.05).
The vast majority of patients with mild OSAS are said
to have the presence and severity of symptoms associated
with body position and often show position-related apnea.
It may cause partial or entire blockage in the airway in the
supine position especially due to the retraction of the chin
and tongue [11]. In mild OSAS, it has been shown that
there is a lower apnea index and better sleep efficiency in
the position dependent group comparing to the
nonposition dependent group [44]. At the beginning of
this study, it was observed that the mean AHI in the
nonsupine position was 4.3 ± 3.84 while it was 16.3 ±
12.34 in the supine position. Similarly, it was shown in
another study that the AHI value decreased by more than
approximately 50% when switching from supine to lateral
position [45]. In this study, it was observed that the
decrease in supine position was statistically significant
even though there was a decrease in AHI value in
nonsupine position after vitamin D supplementation (p =
0.009). Positional therapy is often used for mild OSAS, but
it has only moderate efficacy and poor compatibility [11].
In this study, when respiratory events were examined
according to nonsupine sleep position in mild OSAS with
the support of vitamin D, there was a significant decrease
in the number of apnea + hypopnea (p = 0.017); in
addition to AHI value, the number of hypopnea, apnea +
hypopnea index and hypopnea index significantly
decreased (p < 0.05) in the supine position. It is thought
that the decrease in especially supine position is
important in mild OSAS. In case of vitamin D insufficiency,
it is thought that vitamin D supplementation may have a
positive effect in the treatment of position-related
respiratory events in mild OSAS.
In a meta-analysis that examined the effect of loss of
body weight by intraoral device, CPAP, exercise, and diet,
CPAP treatment was shown to be the most effective
method for the development of saturation during sleep in
complete solution of OSAS (AHI, reduction in ODI) [46].
Nerfeld et al. [47] found that ODI improved, excessive
daytime sleepiness decreased, but AHI did not decrease
with 13% body weight loss in 33 obese OSAS individuals.
In the present study, both AHI and ODI (p = 0.014)
decreased significantly with the support of vitamin D.
However, there was no significant change in the mean
SpO2. Although it was observed that there was an increase

in the sleep time, in which SpO2 was above 90% (90%–
100%), after the use of vitamin D, this increase was not
significant (p = 0.053). Studies to be carried out by
increasing the number of samples can be effective in
seeing this significance.
The present study has some limitations. Firstly, the
control group could not be included in the study due to the
low number of individuals diagnosed with mild OSAS.
Because, generally individuals with severe and moderate
OSAS apply to the Sleep Disorders Center. Secondly, since
this disease is seen more frequently in men and the
proportion of men applying to the study center is higher,
only male individuals were included in the study. Besides,
the study is the first study on vitamin D supplementation
in mild OSAS in Turkey. We think this study will be useful
for further studies on this issue.
5. Conclusion
The low rate of CPAP acceptance/use in mild OSAS
suggests the need to try different treatment practices in
mild OSAS. For this purpose, this study was planned to
investigate the effect of vitamin D supplementation on
disease prognosis and biochemical parameters in mild
OSAS patients with vitamin D deficiency. At the end of the
study, it was observed that vitamin D supplementation
had a positive effect especially on the regulation of insulin
resistance and lipid profile and on many sleep parameters.
In mild OSAS, which is known to increase in severity as the
disease progresses, monitoring the serum vitamin D levels
of patients and vitamin D supplementation in case of
deficiency and insufficiency may be a preventive
treatment to prevent the course of the disease from
worsening.
However,
studies
on
vitamin
D
supplementation in OSAS are quite limited in the
literature. For this reason, it is thought that studies with
higher sample sizes that can clearly demonstrate the
effects of vitamin D use and the dose and duration of
vitamin D in OSAS are needed.
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